News about Clinical Trials

Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval

Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.

Clinical Trials | 26/08/2026 | By News Bureau

Astellas Doses First Patient in Phase 3 ASP2138 Study for Gastric Cancer

Astellas doses the first patient in its phase 3 ASP2138 study for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction cancer.

Clinical Trials | 26/08/2026 | By News Bureau

Milestone Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Etripamil for AFib-RVR

Milestone Pharmaceuticals has begun its Phase 3 ReVeRA-301 trial to evaluate self-administered etripamil nasal spray for acute AFib-RVR, targeting rapid ventricular rate reduction and symptom relief.

Clinical Trials | 24/08/2026 | By News Bureau

Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Clinical Trial in China

Akeso has received NMPA clinical trial clearance for AK157D1, a next-generation B7-H3-targeting ADC, paving the way for a Phase I study in patients with advanced solid tumours in China.

Clinical Trials | 24/08/2026 | By News Bureau

OncoC4 Doses First Patient in Phase 1 Trial of ONC-783 T-Cell Engager

OncoC4 has dosed the first patient in its Phase 1 ONC-783-001 trial, evaluating the investigational T-cell engager ONC-783, developed to target the cancer-specific neoCD24 epitope in patients with advanced solid tumours.

Clinical Trials | 18/08/2026 | By News Bureau

argenx Reports Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis

argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis, meeting the primary endpoint with sustained patient improvements.

Clinical Trials | 17/08/2026 | By News Bureau

Laekna's LAE002 Breast Cancer Drug Application Accepted by China's NMPA

Laekna has advanced LAE002 toward potential commercialisation in China after the NMPA accepted its NDA for afuresertib in patients with advanced HR+/HER2- breast cancer.

Clinical Trials | 12/08/2026 | By News Bureau |  110

Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer

Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.

Clinical Trials | 10/08/2026 | By News Bureau

World-First Fridge-Free Tetanus-Diphtheria Vaccine Trial Shows Promising Results

Stablepharma’s SPVX02 remains potent for up to two years at temperatures of up to 30°C, potentially reducing cold-chain dependence, vaccine wastage and barriers to immunisation in remote regions.

Clinical Trials | 10/08/2026 | By News Bureau

Obsidian Enrols First Patient in Pivotal-Pathway Study of Engineered TIL Therapy

The phase 1/2 Agni-01 cohort will evaluate amsoki-cel in ICI-resistant advanced melanoma, with enrollment expected to conclude by Q1 2027 and topline data anticipated by year-end 2027.<br />

Clinical Trials | 10/08/2026 | By News Bureau